Loading…
Based on limited metadata, the FDA issued a warning letter to Alchymars ICM SM Private Limited on February 16, 2018, regarding an unspecified product category classified as "Other." Without access to the full letter text or detailed subject information, the specific nature of the regulatory violations cannot be determined from the available metadata. The issuing office is also not identified in this record, limiting clarity on the regulatory pathway or product category involved. Further review of the complete warning letter would be necessary to understand the company's compliance failures and required corrective actions.